Canada markets open in 6 hours 8 minutes

Inventiva S.A. (IVA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.6000-0.1100 (-2.34%)
At close: 11:18AM EDT
Full screen
Loading interactive chart...
  • GlobeNewswire

    Inventiva Reports 2022 First-Half Financial Information¹

    Cash position2 at €87.2 m as of June 30, 2022Revenues of €0.1 m in H1 2022Inventiva entered into a finance loan and a warrant agreement for up to €50 million with the European Investment Bank (EIB)Inventiva raised approximately €14.6m through a combination of its At-The-Market program (for €9.3m in gross proceeds) and new State backed bank financing (for €5.3m)Cash runway extended until the end of second quarter 2023 without taking into account the €50m finance loan from the EIB Daix (France), L

  • GlobeNewswire

    Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

    Daix (France), Long Island City (New York, United States), July 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available

  • GlobeNewswire

    Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D

    The Phase IIa Proof-of-Concept study is designed to assess the safety and efficacy of lanifibranor in combination with the SGLT2 inhibitor empagliflozin for the treatment of patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and type-2 diabetes (T2D)The primary efficacy endpoint will be based on improvement in HbA1c Secondary efficacy endpoints include changes in liver enzymes, markers of glycemic control, lipid metabolism, inflammation and body fat compositionPublication of toplin